Andreas Halvorsen's Strategic Acquisition in Longboard Pharmaceuticals

Yahoo FinanceJul 15 19:01 ET

Express News | Longboard Pharmaceuticals Inc : Baird Raises Target Price to $60 From $36

ReutersJul 12 01:56 ET

Baird Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $60

Baird analyst Joel Beatty maintains $Longboard Pharmaceuticals(LBPH.US)$ with a buy rating, and adjusts the target price from $36 to $60.According to TipRanks data, the analyst has a success rate of 4

Moomoo NewsJul 11 07:34 ET · Ratings

Baird Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $60

Baird analyst Joel Beatty maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $36 to $60.

BenzingaJul 11 07:12 ET

Express News | Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersJul 3 16:00 ET

Top 3 Health Care Stocks That May Crash This Quarter

As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator

BenzingaJul 3 09:41 ET